Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer

Cancer Science

Volumn 101, Issue 3, 2010, Pages 601-608

  Uemura, Hirotsugu ^a   Fujimoto, Kiyohide ^b   Mine, Takashi ^c,d   Uejima, Shigeya ^a   de Velasco, Marco A ^a   Hirao, Yoshihiko ^b   Komatsu, Nobukazu ^c   Yamada, Akira ^c   Itoh, Kyogo ^c  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CISPLATIN; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; GONADORELIN; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ARTICLE; BONE METASTASIS; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HUMAN; INJECTION SITE ERYTHEMA; LOCAL SKIN REACTION; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PRURITUS; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CANCER VACCINES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 77949636391     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01459.x     Document Type: Article

References (29)

1. Tannock IF, de Wit R, Berry WR. TAX 327 investigators. N Engl J Med 2004, 351:1502-12.
2. Petrylak DP, Tangen CM, Hussain MH. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-20.
3. Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: current status and future potential. BioDrugs 2008, 22:71-84.
4. Higano CS, Corman JM, Smith DC. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogenic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-84.
5. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006, 97:970-6.
6. Noguchi M, Kobayashi K, Suetsugu N. Cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003, 57:80-92.
7. Noguchi M, Itoh K, Suekane S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 2004, 95:77-84.
8. Noguchi M, Itoh K, Suekane S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004, 60:32-45.
9. Noguchi M, Itoh K, Yao A. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005, 63:1-12.
10. Noguchi M, Mine T, Yamada A. Combination therapy of personalized peptide vaccination with low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 2007, 16:341-9.
11. Naito M, Itoh K, Komatsu N. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 2008, 68:1753-62.
12. Inoue Y, Takaue Y, Takei M. Induction of tumor sprcific cytotoxic T lymphocytes in prostate cancer using prostate acid phosphatase derived HLA-A2402 binding peptide. J Urol 2001, 166:1508-13.
13. Harada M, Kobayashi K, Matsueda S. Prostatic specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate 2003, 57:152-9.
14. Kobayashi K, Noguchi M, Itoh K, Harada M. Identification of a prostatic-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 2003, 94:622-7.
15. Harada M, Noguchi M, Itoh K. Target molecules in sprcific immunotherapy against prostate cancer. Int J Clin Oncol 2003, 8:193-9.
16. Yang D, Nakao M, Shichijo S. Idetication of a gene cording for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59:4056-63.
17. Gomi S, Nakao M, Niiya F. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. J Immunol 1999, 163:4994-5004.
18. Harashima N, Tanaka K, Sasatomi T. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2000, 31:323-32.
19. Matsueda S, Kobayashi K, Nonaka Y, Noguchi M, Itoh K, Harada M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004, 53:479-89.
20. Matsuda Y, Yao A, Ishihara Y. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004, 60:205-13.
21. Yao A, Harada M, Matsueda S. Identification of parathyroid hormonr-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. Br J Cancer 2004, 91:287-96.
22. Yao A, Harada M, Matsueda S. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Prostate 2005, 62:233-42.
23. Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep 2004, 12:601-7.
24. Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptide immunogenic in HLA-A-24+ prostate cancer patients. Prostate 2004, 60:273-81.
25. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, version 3.0. [Aug. 9, 2006]:
26. Therasse H, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 92:205-216.
27. Yajima N, Yamanaka Y, Mine T. Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005, 11:5900-11.
28. Minami T, Matsuda S, Takedatsu H. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 super type alleles. Cancer Immunol Immunother 2007, 56:689-98.
29. Uemura H, Fujimoto K, Tanaka M. A phase I trial of vaccination of CA9-derived peptides for HLA-A24 positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006, 12:1768-75.